impact
increas
resist
microorgan
drug
specif
antimicrobi
substanc
motiv
sever
research
group
sinc
discoveri
antimicrobi
peptid
amp
conquer
special
attent
import
therapeut
altern
prevent
treatment
infect
caus
larg
number
microorgan
oyston
et
al
amp
univers
featur
defens
system
form
life
repres
found
organ
rang
bacteria
plant
invertebr
vertebr
speci
includ
mammal
jenssen
et
al
studi
antivir
compound
date
felip
et
al
sever
reason
seriou
side
effect
drug
approv
clinic
use
de
clercq
antimicrobi
activ
report
among
sever
bacteria
isol
aquat
environ
brazilian
amazon
basin
motta
et
al
among
speci
bacillu
produc
antimicrobi
peptid
isol
intestin
content
fish
piaucompinta
leporinu
sp
motta
et
al
peptid
purifi
name
antimicrobi
activ
character
fengycinlik
substanc
motta
et
al
inhibitori
activ
detect
gramposit
bacteria
like
listeria
monocytogen
bacillu
cereu
motta
et
al
gramneg
bacteria
like
escherichia
coli
salmonella
enteritidi
motta
et
al
studi
shown
import
potenti
food
preserv
motta
et
al
littl
attent
address
applic
antimicrobi
substanc
clinic
studi
sinc
data
regard
antivir
activ
peptid
aim
present
work
evalu
activ
exert
peptid
canin
adenoviru
canin
coronaviru
ccov
canin
distemp
viru
cdv
canin
parvoviru
type
equin
arter
viru
eav
equin
influenza
viru
eiv
felin
caliciviru
fcv
felin
herpesviru
type
peptid
produc
describ
elsewher
motta
et
al
purif
total
protein
concentr
measur
triplic
lowri
method
accord
manufactur
protocol
total
protein
kit
micro
lowri
peterson
modif
sigma
aldrich
usa
purifi
peptid
analyz
mass
spectrometri
stein
ettan
malditof
prosystem
amersham
bioscienc
sweden
oper
reflectron
mode
posit
ioniz
kv
use
matrix
acid
sigmaaldrich
usa
peptid
store
use
antivir
assay
madindarbi
canin
kidney
mdck
number
usa
crandellre
felin
kidney
crfk
number
usa
rabbit
kidney
number
usa
cell
cultiv
eagl
minimum
essenti
medium
emem
sigma
aldrich
usa
supplement
bovin
fetal
serum
bf
gibco
usa
penicillin
sigmaaldrich
usa
streptomycin
vetec
brasil
amphotericin
b
brasil
enrofloxacin
bayer
brasil
incub
antivir
activ
amp
evalu
virus
differ
phenotyp
genotyp
featur
fcv
weiblen
et
al
ccov
mav
strain
eav
bucyru
strain
eiv
local
isol
kindli
provid
virolog
laboratori
feder
univers
santa
maria
ufsm
toronto
strain
cdv
lederl
strain
cornel
strain
strain
kindli
provid
finamor
veterinari
research
institut
ipvdf
virus
propag
mdck
crfk
cell
cultur
mdck
crfk
cell
grown
micropl
tpp
switzerland
incub
differ
concentr
h
cell
viabil
measur
neutral
red
dye
uptak
nru
vetec
brasil
assay
borenfreund
puerner
bromid
mtt
sigmaaldrich
usa
procedur
mosmann
percentag
cell
viabil
cv
calcul
cv
ac
ac
absorb
treat
control
cell
respect
vaucher
et
al
cytotox
express
concentr
cytotox
observ
inhibit
cpe
assay
perform
confluent
mdck
crfk
cell
monolay
presenc
absenc
noncytotox
concentr
cell
lineag
describ
result
endpoint
titrat
perform
describ
elsewher
mahi
kangro
titer
express
tissu
cultur
infect
dose
cell
kept
incub
observ
cpe
h
viral
percent
inhibit
pi
calcul
pi
titer
treat
titer
control
adapt
felip
et
al
viru
strain
incub
h
emem
presenc
absenc
noncytotox
concentr
cell
lineag
incub
period
infect
immedi
determin
viru
titrat
cell
cultur
assay
perform
triplic
statist
analysi
perform
use
twotail
student
ttest
valu
consid
signific
p
mass
spectrum
purifi
peptid
reveal
typic
mz
peak
lipopeptid
fengycin
figur
mz
peak
differ
da
equival
group
peak
assign
form
peak
correspond
na
k
adduct
fengycin
also
observ
order
distinguish
select
antivir
activ
cytotox
peptid
evalu
mdck
crfk
cell
nru
mtt
assay
quit
similar
nru
mtt
test
cell
lineag
valu
mdck
crfk
cell
respect
cytotox
observ
peptid
mdck
crfk
cell
cultur
concentr
use
subsequ
assay
titrat
show
presenc
peptid
statist
signific
effect
p
product
viral
particl
ccov
cdv
eiv
fcv
howev
signific
reduct
viral
titer
occur
respect
incub
eav
tabl
titer
eav
express
reduc
presenc
present
pi
titer
presenc
absenc
result
pi
peptid
direct
inactiv
effect
eav
infecti
particl
potent
virucid
effect
observ
eav
infect
reduc
h
incub
eav
titer
reduc
presenc
p
great
number
peptid
isol
differ
sourc
studi
antivir
activ
andreu
riva
antimicrobi
peptid
databas
apd
http
apsunmceduapmainhtml
sever
amp
test
reach
clinic
routin
oevermann
et
al
wachsman
et
al
ideal
use
antimicrobi
agent
exhibit
broadspectrum
antimicrobi
activ
mohan
et
al
anion
thermost
hydrophob
lipid
bacteriocinlik
substanc
produc
bacillu
sp
antimicrobi
properti
bacteria
motta
et
al
virus
accord
present
studi
howev
anion
antimicrobi
peptid
rare
paulmann
et
al
thought
peptid
develop
respons
resist
mechan
toward
cation
antimicrobi
peptid
lai
et
al
found
speci
potenti
broadspectrum
antivir
agent
albiolmatan
castilla
order
evalu
peptid
antivir
substanc
vitro
expos
amp
dna
virus
envelop
felip
et
al
decaro
buonavoglia
san
rna
virus
test
ccov
cdv
eav
eiv
fcv
envelop
virus
except
fcv
seki
et
al
abdeldaim
et
al
diel
et
al
gorbalenya
et
al
decaro
et
al
accord
assay
perform
seem
peptid
broad
antivir
activ
sinc
inhibit
eav
peptid
demonstr
abil
kill
rapidli
broad
rang
microorgan
includ
multidrug
resist
bacteria
fungi
virus
lytic
membran
properti
reddi
et
al
amp
like
surfactin
magainin
mellitin
cecropin
known
abil
interact
lipid
membran
result
destabil
transloc
pore
format
lysi
vollenbroich
et
al
sitaram
nagaraj
possibl
peptid
interfer
adsorpt
penetr
viral
replic
even
exert
competit
viral
particl
cellular
receptor
use
eav
infect
block
viral
entri
may
occur
specif
interact
cellular
receptor
viral
envelop
compound
apart
viral
glycoprotein
jenssen
et
al
possibl
mechan
propos
explain
activ
would
interact
cellular
receptor
like
heparan
sulfat
even
block
certain
viral
glycoprotein
heparan
sulfat
import
glycosaminoglycan
molecul
associ
herpesviru
attach
host
cell
spillmann
luganini
et
al
consequ
interfer
heparan
sulfat
reduc
viral
infect
shieh
et
al
virucid
activ
may
due
physicochem
interact
membraneact
surfact
viru
lipid
membran
similarli
fengycin
steller
et
al
altern
peptid
eavspecif
viral
inactiv
detect
envelop
virus
test
hypothes
peptid
inactiv
viru
interact
nonlipid
structur
compon
eav
member
famili
arterivirida
belong
order
nidoviral
along
porcin
respiratori
reproduct
syndrom
viru
simian
hemorrhag
fever
viru
lactat
dehydrogenas
elev
viru
de
vri
et
al
gorbalenya
et
al
although
equin
viral
arter
caus
sever
econom
loss
equin
industri
specif
treatment
timoney
mccollum
thu
need
develop
antivir
drug
treatment
diseas
herpesvirus
cosmopolit
agent
caus
sever
infect
human
anim
especi
immunocompromis
individu
felip
et
al
remark
featur
member
famili
abil
caus
reactiv
latent
infect
host
import
control
diseas
et
al
among
drug
possess
inhibitori
action
herpesviru
replic
use
human
medicin
nucleosid
analogu
de
clercq
evid
resist
de
clercq
likewis
necessari
search
new
compound
altern
mechan
action
effect
antivir
agent
lack
specif
target
rna
virus
li
et
al
current
antivir
drug
armamentarium
compris
compound
offici
approv
clinic
use
howev
approv
drug
use
treatment
human
immunodefici
viru
infect
felip
et
al
fast
increas
pathogen
dissemin
resist
drug
forc
scientist
consid
altern
method
overcom
infect
motta
et
al
mainli
emerg
reemerg
viral
infect
li
et
al
therefor
mani
amp
produc
natur
may
becom
altern
control
specif
pathogen
infect
riley
wertz
accord
present
studi
peptid
may
interest
therapeut
prospect
treatment
hors
cat
affect
eav
respect
howev
detail
studi
vitro
vivo
must
perform
elucid
specif
mechan
action
peptid
virus
summari
result
indic
peptid
show
antivir
activ
eav
virucid
properti
eav
nevertheless
antivir
activ
detect
ccov
cdv
eiv
fcv
